Alseres Pharmaceuticals, Inc. (ALSE)
USD 0.01
(100.0%)
USD 0.01
(100.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2013 | 1.41 Million USD | -17.28% |
| 2012 | 1.71 Million USD | 9.67% |
| 2011 | 1.56 Million USD | -49.88% |
| 2010 | 3.12 Million USD | -62.49% |
| 2009 | 8.32 Million USD | -55.5% |
| 2008 | 18.71 Million USD | -0.9% |
| 2007 | 18.88 Million USD | -28.57% |
| 2006 | 26.43 Million USD | 126.95% |
| 2005 | 11.64 Million USD | 12.2% |
| 2004 | 10.38 Million USD | 31.16% |
| 2003 | 7.91 Million USD | -23.17% |
| 2002 | 10.3 Million USD | -2.68% |
| 2001 | 10.58 Million USD | -7.78% |
| 2000 | 11.47 Million USD | -11.02% |
| 1999 | 12.9 Million USD | 65.38% |
| 1998 | 7.8 Million USD | -16.13% |
| 1997 | 9.3 Million USD | 72.22% |
| 1996 | 5.4 Million USD | 38.46% |
| 1995 | 3.9 Million USD | -56.67% |
| 1994 | 9 Million USD | -69.39% |
| 1993 | 29.4 Million USD | 50.0% |
| 1992 | 19.6 Million USD | -2.49% |
| 1991 | 20.1 Million USD | 33.11% |
| 1990 | 15.1 Million USD | 29.06% |
| 1989 | 11.7 Million USD | -12.69% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2014 Q1 | 348.15 Thousand USD | 18.3% |
| 2014 Q2 | 334.63 Thousand USD | -3.88% |
| 2013 Q2 | 370.92 Thousand USD | -15.64% |
| 2013 Q4 | 294.29 Thousand USD | -6.54% |
| 2013 FY | 1.41 Million USD | -17.28% |
| 2013 Q3 | 314.89 Thousand USD | -15.11% |
| 2013 Q1 | 439.68 Thousand USD | 30.28% |
| 2012 Q2 | 439.22 Thousand USD | -5.96% |
| 2012 Q4 | 337.48 Thousand USD | -28.59% |
| 2012 FY | 1.71 Million USD | 9.67% |
| 2012 Q1 | 467.05 Thousand USD | 307.91% |
| 2012 Q3 | 472.59 Thousand USD | 7.6% |
| 2011 FY | 1.56 Million USD | -49.88% |
| 2011 Q2 | 629.64 Thousand USD | 1.03% |
| 2011 Q4 | -224.64 Thousand USD | -141.84% |
| 2011 Q3 | 536.87 Thousand USD | -14.73% |
| 2011 Q1 | 623.19 Thousand USD | 177.22% |
| 2010 Q3 | 733.66 Thousand USD | -23.7% |
| 2010 Q4 | 224.8 Thousand USD | -69.36% |
| 2010 Q1 | 1.2 Million USD | 7.71% |
| 2010 Q2 | 961.54 Thousand USD | -20.0% |
| 2010 FY | 3.12 Million USD | -62.49% |
| 2009 Q2 | 1.98 Million USD | -47.73% |
| 2009 FY | 8.32 Million USD | -55.5% |
| 2009 Q4 | 1.11 Million USD | -21.76% |
| 2009 Q1 | 3.79 Million USD | 2.76% |
| 2009 Q3 | 1.42 Million USD | -28.16% |
| 2008 Q2 | 5.58 Million USD | 13.99% |
| 2008 Q1 | 4.9 Million USD | -3.61% |
| 2008 FY | 18.71 Million USD | -0.9% |
| 2008 Q4 | 3.69 Million USD | -18.26% |
| 2008 Q3 | 4.52 Million USD | -19.09% |
| 2007 FY | 18.88 Million USD | -28.57% |
| 2007 Q4 | 5.08 Million USD | 13.77% |
| 2007 Q1 | 4.17 Million USD | -70.98% |
| 2007 Q2 | 5.14 Million USD | 23.25% |
| 2007 Q3 | 4.47 Million USD | -13.13% |
| 2006 Q1 | 4.04 Million USD | 21.26% |
| 2006 FY | 26.43 Million USD | 126.95% |
| 2006 Q3 | 4.02 Million USD | 1.48% |
| 2006 Q2 | 3.96 Million USD | -1.97% |
| 2006 Q4 | 14.39 Million USD | 257.44% |
| 2005 Q2 | 2.43 Million USD | 5.5% |
| 2005 Q1 | 2.3 Million USD | 45.6% |
| 2005 FY | 11.64 Million USD | 12.2% |
| 2005 Q3 | 3.75 Million USD | 54.59% |
| 2005 Q4 | 3.33 Million USD | -11.15% |
| 2004 Q2 | 3.85 Million USD | 49.92% |
| 2004 Q4 | 1.58 Million USD | -33.37% |
| 2004 Q3 | 2.37 Million USD | -38.4% |
| 2004 Q1 | 2.57 Million USD | 42.77% |
| 2004 FY | 10.38 Million USD | 31.16% |
| 2003 Q2 | 1.88 Million USD | -19.49% |
| 2003 Q4 | 1.8 Million USD | -5.13% |
| 2003 Q3 | 1.89 Million USD | 0.94% |
| 2003 FY | 7.91 Million USD | -23.17% |
| 2003 Q1 | 2.33 Million USD | 5.16% |
| 2002 FY | 10.3 Million USD | -2.68% |
| 2002 Q4 | 2.22 Million USD | -11.75% |
| 2002 Q1 | 2.97 Million USD | 29.99% |
| 2002 Q2 | 2.58 Million USD | -13.01% |
| 2002 Q3 | 2.51 Million USD | -2.77% |
| 2001 Q3 | 2.73 Million USD | -12.53% |
| 2001 Q4 | 2.28 Million USD | -16.23% |
| 2001 FY | 10.58 Million USD | -7.78% |
| 2001 Q1 | 2.43 Million USD | 31.06% |
| 2001 Q2 | 3.12 Million USD | 28.05% |
| 2000 Q4 | 1.86 Million USD | -43.66% |
| 2000 Q2 | 3.58 Million USD | 36.01% |
| 2000 Q1 | 2.63 Million USD | -58.22% |
| 2000 FY | 11.47 Million USD | -11.02% |
| 2000 Q3 | 3.3 Million USD | -7.71% |
| 1999 Q3 | 2.5 Million USD | 38.89% |
| 1999 FY | 12.9 Million USD | 65.38% |
| 1999 Q4 | 6.3 Million USD | 152.0% |
| 1999 Q2 | 1.8 Million USD | -18.18% |
| 1999 Q1 | 2.2 Million USD | 4.76% |
| 1998 FY | 7.8 Million USD | -16.13% |
| 1998 Q3 | 1.8 Million USD | -5.26% |
| 1998 Q1 | 1.7 Million USD | -29.17% |
| 1998 Q4 | 2.1 Million USD | 16.67% |
| 1998 Q2 | 1.9 Million USD | 11.76% |
| 1997 Q1 | 2.1 Million USD | 31.25% |
| 1997 FY | 9.3 Million USD | 72.22% |
| 1997 Q4 | 2.4 Million USD | 4.35% |
| 1997 Q3 | 2.3 Million USD | -8.0% |
| 1997 Q2 | 2.5 Million USD | 19.05% |
| 1996 Q2 | 1.1 Million USD | -15.38% |
| 1996 FY | 5.4 Million USD | 38.46% |
| 1996 Q4 | 1.6 Million USD | 33.33% |
| 1996 Q3 | 1.2 Million USD | 9.09% |
| 1996 Q1 | 1.3 Million USD | 8.33% |
| 1995 Q3 | 1.1 Million USD | 57.14% |
| 1995 Q1 | 600 Thousand USD | 20.0% |
| 1995 FY | 3.9 Million USD | -56.67% |
| 1995 Q4 | 1.2 Million USD | 9.09% |
| 1995 Q2 | 700 Thousand USD | 16.67% |
| 1994 Q2 | 3.7 Million USD | 164.29% |
| 1994 Q1 | 1.4 Million USD | -88.52% |
| 1994 Q4 | 500 Thousand USD | -44.44% |
| 1994 Q3 | 900 Thousand USD | -75.68% |
| 1994 FY | 9 Million USD | -69.39% |
| 1993 Q3 | 5.7 Million USD | 14.0% |
| 1993 Q1 | 6.3 Million USD | -1.56% |
| 1993 FY | 29.4 Million USD | 50.0% |
| 1993 Q4 | 12.2 Million USD | 114.04% |
| 1993 Q2 | 5 Million USD | -20.63% |
| 1992 Q2 | 1.1 Million USD | 10.0% |
| 1992 Q4 | 6.4 Million USD | 16.36% |
| 1992 Q3 | 5.5 Million USD | 400.0% |
| 1992 Q1 | 1 Million USD | -94.01% |
| 1992 FY | 19.6 Million USD | -2.49% |
| 1991 Q1 | 1 Million USD | 106.76% |
| 1991 Q3 | 1.1 Million USD | 0.0% |
| 1991 Q2 | - USD | -100.0% |
| 1991 FY | 20.1 Million USD | 33.11% |
| 1991 Q4 | 16.7 Million USD | 1418.18% |
| 1990 Q4 | -14.8 Million USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q1 | - USD | 100.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 FY | 15.1 Million USD | 29.06% |
| 1989 FY | 11.7 Million USD | -12.69% |
| 1989 Q3 | - USD | 0.0% |
| 1989 Q1 | - USD | 100.0% |
| 1989 Q2 | - USD | 0.0% |
| 1989 Q4 | -11.5 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -6.317% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 71.841% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 95.196% |
| Nascent Biotech, Inc. | 2.22 Million USD | 36.329% |
| Rebus Holdings, Inc. | 664 Thousand USD | -113.824% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 96.189% |
| Qrons Inc. | 643.67 Thousand USD | -120.575% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -264.455% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 97.528% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -241.724% |
| Skye Bioscience, Inc. | 13.54 Million USD | 89.52% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.364% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 71.13% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -442.473% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.342% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 51.314% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 5.467% |
| Mesoblast Limited | 5.9 Million USD | 75.944% |
| Marizyme, Inc. | 19.23 Million USD | 92.621% |
| Genus plc | 147.7 Million USD | 99.039% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 83.828% |
| Pharming Group N.V. | 225.49 Million USD | 99.37% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 30.698% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -5.833% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 82.974% |
| ContraFect Corporation | 56.88 Million USD | 97.504% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 67.795% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 3.987% |
| IMV Inc. | 37.7 Million USD | 96.235% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 49.118% |
| MultiCell Technologies, Inc. | 567.42 USD | -250118.885% |
| ONE Bio Corp. | 6.44 Million USD | 77.967% |
| Accustem Sciences Inc. | 3.74 Million USD | 62.103% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.348% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -166.897% |
| Q BioMed Inc. | 3.43 Million USD | 58.686% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 94.255% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 45.965% |
| Biomind Labs Inc. | 994.18 Thousand USD | -42.81% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.571% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 19.315% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 78.866% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 23.846% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 5779.168% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 91.132% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 22.631% |
| GB Sciences, Inc. | 1.42 Million USD | 0.05% |
| Alpha Cognition Inc. | 9.7 Million USD | 85.371% |
| HST Global, Inc. | 140.9 Thousand USD | -907.609% |
| CSL Limited | 3.44 Billion USD | 99.959% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -26.214% |
| Halberd Corporation | 74.84 Thousand USD | -1797.052% |
| Enzolytics Inc. | 2.17 Million USD | 34.857% |
| Agentix Corp. | 1.37 Million USD | -3.502% |
| Resverlogix Corp. | 12.71 Million USD | 88.831% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 61.109% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.907% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -35.995% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 40.963% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 10.103% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 58.302% |
| AVAX Technologies, Inc. | 7.31 Million USD | 80.578% |
| Zenith Capital Corp. | 8.94 Million USD | 84.124% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.828% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -8049.888% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 42.175% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -727.824% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 26.087% |
| Kadimastem Ltd | 2.41 Million USD | 41.09% |
| Helix BioMedix, Inc. | 1.97 Million USD | 28.004% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 86.935% |
| BioStem Technologies, Inc. | 22.97 Million USD | 93.82% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -682.319% |
| LadRx Corporation | 3.81 Million USD | 62.753% |
| Cell Source, Inc. | 4.32 Million USD | 67.175% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -53.739% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -53.739% |
| NovAccess Global Inc. | 2.46 Million USD | 42.443% |
| Affymax, Inc. | 39.38 Million USD | 96.395% |
| Itoco Inc. | 919.14 Thousand USD | -54.469% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 66.502% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -26.88% |
| Mobile Lads Corp. | 554.54 Thousand USD | -156.028% |
| CytoDyn Inc. | 18.05 Million USD | 92.138% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -5541.035% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -545.131% |
| SYBLEU INC | 160.87 Thousand USD | -782.538% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 21.831% |
| International Stem Cell Corporation | 5.27 Million USD | 73.064% |
| Bioxytran, Inc. | 3.82 Million USD | 62.834% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2597.071% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -6879.266% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 96.085% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 12.25% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -92.95% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 54.362% |
| Neutra Corp. | 243.82 Thousand USD | -482.309% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 91.867% |
| PureTech Health plc | 144.59 Million USD | 99.018% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 93.071% |
| IXICO plc | 4.7 Million USD | 69.837% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 83.86% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.794% |
| CSL Limited | 3.89 Billion USD | 99.964% |
| Cellectis S.A. | 97.32 Million USD | 98.541% |